HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury DOI Creative Commons
Kenneth K.W. To, Seda S. Tolu,

Longling Wang

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Histone deacetylase inhibitors (HDACIs) are epigenetic drugs that regulate the acetylation status of histones and non-histone proteins, thereby leading to chromatin remodeling transcriptional regulation key apoptotic cell cycle regulatory genes. There currently five HDACIs clinically approved by major authorities for treating hematological cancers, primarily as monotherapy. While have been particularly effective in T-cell lymphomas, their clinical efficacies not yet extended solid tumors. The development continues, including treatment a non-malignant conditions, with givinostat recently US FDA. However, early was limited concerns about cardiotoxicity QT interval prolongation. Yet, paradoxically, latest research suggests some cardioprotective effect ischemic heart disease or failure. This review presents update HDACIs. mechanisms HDACI-induced cardiotoxic adverse events strategies management discussed. We will also deliberate potential repurposing use HDAC isoform selectivity ischemia-reperfusion cardiac muscle injury, hypertrophy, fibrosis.

Language: Английский

The mTOR Signaling Pathway: Key Regulator and Therapeutic Target for Heart Disease DOI Creative Commons

Jieyu Wang,

Yuxuan Huang,

Zhaoxia Wang

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 397 - 397

Published: Feb. 7, 2025

Heart disease, including myocardial infarction, heart failure, cardiac hypertrophy, and cardiomyopathy, remains a leading cause of mortality worldwide. The mammalian target rapamycin (mTOR) is centrally regulated kinase that governs key cellular processes, growth, proliferation, metabolism, survival. Notably, mTOR plays pivotal role in cardiovascular health particularly the onset progression conditions. In this review, we discuss mTOR’s structure function as well regulatory mechanisms its associated signaling pathways. We focus on molecular by which regulates diseases potential inhibitors related drugs preventing these conclude pathway promising therapeutic for disease.

Language: Английский

Citations

1
Frailty DOI Creative Commons
Mina S. Sedrak, Aarti Asnani

JACC CardioOncology, Journal Year: 2025, Volume and Issue: 7(2), P. 122 - 124

Published: Feb. 1, 2025

Citations

0
Anthracycline-induced cardiotoxicity: emerging mechanisms and therapies DOI Creative Commons
Guanjing Ling, Fei Ge, Weili Li

et al.

Medicine Plus, Journal Year: 2025, Volume and Issue: unknown, P. 100074 - 100074

Published: Feb. 1, 2025

Language: Английский

Citations

0
SNP’s use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic DOI
Hebatallah Ahmed Mohamed Moustafa, Walaa A. El‐Dakroury, Alaa Ashraf

et al.

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 22, 2025

Language: Английский

Citations

0
Bridging Cancer and Cardiovascular Health: A Comprehensive Review of Cardiotoxicity in Modern Oncology DOI Creative Commons

Anjali Rajpoot,

Veena Sharma

Heart and Mind, Journal Year: 2025, Volume and Issue: 9(2), P. 115 - 135

Published: March 1, 2025

Abstract As survival rates for cancer patients improve due to advancements in treatment modalities, there is an increasing prevalence of cardiovascular complications, necessitating a comprehensive understanding this intersection. This review aims elucidate the intricate relationship between and disease, highlighting growing concern toxicity associated with therapies. It explores various treatments, including chemotherapy, targeted therapies, radiation, their risks, such as heart failure ischemic disease. In addition, it discusses importance proactive risk assessments ongoing monitoring mitigate adverse outcomes. Strategies prevention management, lifestyle modifications pharmacologic interventions, are also examined support health survivors. Unlike previous reviews, work integrates insights from multidisciplinary collaborations, emphasizing underexplored mechanisms role innovative tools. highlights emerging therapeutic strategies tailored these providing forward-looking perspective critical area research. The need collaborative method that includes oncologists, cardiologists, primary care providers emphasized ensure integrated addresses both health. serves resource healthcare professionals seeking long-term outcomes survivors by recognizing managing risks.

Language: Английский

Citations

0
Metabolic Reprogramming in Cancer Therapy-Related Cardiovascular Toxicity: Mechanisms and Intervention Strategies DOI
Cheng Zeng, Ying Gao, Bo Lan

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury DOI Creative Commons
Kenneth K.W. To, Seda S. Tolu,

Longling Wang

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Histone deacetylase inhibitors (HDACIs) are epigenetic drugs that regulate the acetylation status of histones and non-histone proteins, thereby leading to chromatin remodeling transcriptional regulation key apoptotic cell cycle regulatory genes. There currently five HDACIs clinically approved by major authorities for treating hematological cancers, primarily as monotherapy. While have been particularly effective in T-cell lymphomas, their clinical efficacies not yet extended solid tumors. The development continues, including treatment a non-malignant conditions, with givinostat recently US FDA. However, early was limited concerns about cardiotoxicity QT interval prolongation. Yet, paradoxically, latest research suggests some cardioprotective effect ischemic heart disease or failure. This review presents update HDACIs. mechanisms HDACI-induced cardiotoxic adverse events strategies management discussed. We will also deliberate potential repurposing use HDAC isoform selectivity ischemia-reperfusion cardiac muscle injury, hypertrophy, fibrosis.

Language: Английский

Citations

0